Literature DB >> 22785351

The ERBB network: at last, cancer therapy meets systems biology.

Yosef Yarden1, Gur Pines.   

Abstract

Although it is broadly agreed that the improved treatment of patients with cancer will depend on a deeper molecular understanding of the underlying pathogenesis, only a few examples are already available. This Timeline article focuses on the ERBB (also known as HER) network of receptor tyrosine kinases (RTKs), which exemplifies how a constant dialogue between basic research and medical oncology can translate into both a sustained pipeline of novel drugs and ways to overcome acquired treatment resistance in patients. We track the key early discoveries that linked this RTK family to oncogenesis, the course of pioneering clinical research and their merger into a systems-biology framework that is likely to inspire further generations of effective therapeutic strategies.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22785351     DOI： 10.1038/nrc3309

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  183 in total

1.  Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal.

Authors:  S COHEN
Journal:  J Biol Chem       Date:  1962-05       Impact factor: 5.157

2.  Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

Authors:  Clara Montagut; Alba Dalmases; Beatriz Bellosillo; Marta Crespo; Silvia Pairet; Mar Iglesias; Marta Salido; Manuel Gallen; Scot Marsters; Siao Ping Tsai; André Minoche; Somasekar Seshagiri; Seshagiri Somasekar; Sergi Serrano; Heinz Himmelbauer; Joaquim Bellmunt; Ana Rovira; Jeff Settleman; Francesc Bosch; Joan Albanell
Journal:  Nat Med       Date:  2012-01-22       Impact factor: 53.440

Review 3.  Negative receptor signalling.

Authors:  Ivan Dikic; Silvia Giordano
Journal:  Curr Opin Cell Biol       Date:  2003-04       Impact factor: 8.382

4.  Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development.

Authors:  D Meyer; C Birchmeier
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

5.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

6.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Authors:  R M Hudziak; G D Lewis; M Winget; B M Fendly; H M Shepard; A Ullrich
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

7.  Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts.

Authors:  Y Kokai; J N Myers; T Wada; V I Brown; C M LeVea; J G Davis; K Dobashi; M I Greene
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

8.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors:  A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

Review 9.  Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.

Authors:  Brent N Rexer; Jeffrey A Engelman; Carlos L Arteaga
Journal:  Cell Cycle       Date:  2009-01-30       Impact factor: 4.534

10.  Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor.

Authors:  A B Schreiber; I Lax; Y Yarden; Z Eshhar; J Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205
View more
  332 in total

1.  Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.

Authors:  Chunrong Li; Toni M Brand; Mari Iida; Shyhmin Huang; Eric A Armstrong; Albert van der Kogel; Deric L Wheeler
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

Review 2.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  A critical analysis of cancer biobank practices in relation to biospecimen quality.

Authors:  Amanda Rush; Kevin Spring; Jennifer A Byrne
Journal:  Biophys Rev       Date:  2015-10-22

4.  DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.

Authors:  Katrin Friedrich; Jan Rh Hanauer; Steffen Prüfer; Robert C Münch; Iris Völker; Christodoulos Filippis; Christian Jost; Kay-Martin Hanschmann; Roberto Cattaneo; Kah-Whye Peng; Andreas Plückthun; Christian J Buchholz; Klaus Cichutek; Michael D Mühlebach
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

5.  Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.

Authors:  Gladys Morrison; Xiaoyong Fu; Martin Shea; Sarmistha Nanda; Mario Giuliano; Tao Wang; Teresa Klinowska; C Kent Osborne; Mothaffar F Rimawi; Rachel Schiff
Journal:  Breast Cancer Res Treat       Date:  2014-02-20       Impact factor: 4.872

6.  An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors.

Authors:  S Carvalho; M Lindzen; M Lauriola; N Shirazi; S Sinha; A Abdul-Hai; K Levanon; J Korach; I Barshack; Y Cohen; A Onn; G Mills; Y Yarden
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

7.  Involvement of de novo synthesized palmitate and mitochondrial EGFR in EGF induced mitochondrial fusion of cancer cells.

Authors:  Lakshmi Reddy Bollu; Jiangong Ren; Alicia Marie Blessing; Rajasekhara Reddy Katreddy; Guang Gao; Lei Xu; Jinrong Wang; Fei Su; Zhang Weihua
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method.

Authors:  Eiji Higaki; Takeshi Kuwata; Akiko Kawano Nagatsuma; Yasunori Nishida; Takahiro Kinoshita; Masaki Aizawa; Hiroaki Nitta; Masato Nagino; Atsushi Ochiai
Journal:  Gastric Cancer       Date:  2014-12-09       Impact factor: 7.370

9.  TRAF4 binds to the juxtamembrane region of EGFR directly and promotes kinase activation.

Authors:  Gang Cai; Liang Zhu; Xing Chen; Kevin Sun; Caini Liu; Ganes C Sen; George R Stark; Jun Qin; Xiaoxia Li
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-23       Impact factor: 11.205

10.  Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

Authors:  Glenwood D Goss; Enriqueta Felip; Manuel Cobo; Shun Lu; Konstantinos Syrigos; Ki Hyeong Lee; Erdem Göker; Vassilis Georgoulias; Wei Li; Salih Guclu; Dolores Isla; Young Joo Min; Alessandro Morabito; Andrea Ardizzoni; Shirish M Gadgeel; Andrea Fülöp; Claudia Bühnemann; Neil Gibson; Nicole Krämer; Flavio Solca; Agnieszka Cseh; Eva Ehrnrooth; Jean-Charles Soria
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.